Related Experiment Video

Updated: Jan 23, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

363

A new small cell lung cancer biomarker identified by Cell-SELEX generated aptamers

Wei Zhou1, Libo Zhao2, Hongyu Yuan3

  • 1Beijing National Research Center for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, PR China; University of Chinese Academy of Sciences, Beijing, 100049, PR China.

Experimental Cell Research
|June 25, 2019
PubMed

Insights

Researchers identified high-density lipoprotein binding protein (HDLBP) as a novel biomarker for small cell lung cancer (SCLC). Targeting HDLBP shows promise for improving SCLC treatment and demonstrates the utility of cell-SELEX in cancer research.

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Small cell lung cancer (SCLC) remains a challenging malignancy with limited therapeutic advancements over the last 30 years.
  • The absence of effective targeted therapies necessitates the identification of new druggable biomarkers for SCLC.
  • Developing novel therapeutic strategies is critical for improving outcomes in SCLC patients.

Purpose of the Study:

  • To identify and validate novel protein biomarkers for small cell lung cancer.
  • To investigate the functional role of identified biomarkers in SCLC progression.
  • To explore the therapeutic potential of targeting novel biomarkers in SCLC.

Main Methods:

  • Cell-based systematic evolution of ligands by exponential enrichment (cell-SELEX) was employed to generate aptamers against SCLC cells.
  • Immunohistochemistry was used to assess biomarker expression in clinical SCLC tissue samples.
  • Small interfering RNA (siRNA) was utilized to attenuate biomarker expression, and proliferation, metastasis, and tumor formation assays were performed in vitro and in vivo.

Main Results:

  • High-density lipoprotein binding protein (HDLBP) was identified as a novel SCLC biomarker.
  • Elevated HDLBP levels were observed in clinical SCLC tissues.
  • Inhibition of HDLBP suppressed SCLC cell proliferation, metastasis, and tumor growth, revealing its role in promoting G1/S cell cycle transition.

Conclusions:

  • HDLBP is a promising therapeutic target for improving small cell lung cancer treatment.
  • Targeting HDLBP offers a potential new strategy for SCLC therapy.
  • Cell-SELEX is a powerful tool for biomarker discovery in cancer medicine.
Keywords:
AptamerCell cycleHDLBPSmall cell lung cancerTargeted therapy

More Related Videos

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

Related Concept Videos

Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells01:18

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells

A stem cell is an unspecialized cell that can divide without limit as needed and can, under specific conditions, differentiate into specialized cells.
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...
4.5K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K